A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study

The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.

Start Date16 Dec 2024

Sponsor / Collaborator

Insmed, Inc.

NCT06344728

/ CompletedPhase 1

A Phase 1, Open-Label, Randomized, Two-Period Crossover Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets Following Single Oral Doses in Healthy Subjects

The primary purpose of this study is to determine the relative bioavailability of brensocatib between the pediatric oral solution and oral tablets in healthy participants.

Start Date30 Apr 2024

Sponsor / Collaborator

Insmed, Inc.

NCT06178783

/ CompletedPhase 1

A Phase 1, Double-blind, Randomized, Single-center Study to Assess the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Subjects

The primary purpose of this study is to assess the palatability and compare acceptability of brensocatib oral solutions.

Start Date27 Dec 2023

Sponsor / Collaborator

Insmed, Inc.

100 Clinical Results associated with Brensocatib

100 Translational Medicine associated with Brensocatib

100 Patents (Medical) associated with Brensocatib

Literatures (Medical) associated with Brensocatib

01 Apr 2026·CURRENT OPINION IN INFECTIOUS DISEASES

Anti-inflammatory therapies for bronchiectasis

Review

Author: Bautista, Jennifer ; Metersky, Mark L.

Purpose of review:

Bronchiectasis is a condition that is characterized by chronic airway inflammation and usually infection, resulting in progressive airway damage. It results in a significant symptom burden and impacts both clinical and socioeconomic aspect of a patient's life. This review will detail anti-inflammatory treatment options for bronchiectasis, their benefits and possible side effects.

Recent findings:

Inflammation is the main driver of bronchiectasis disease progression and has been the focus of research for many years. Inhaled corticosteroids, though not routinely recommended in guidelines, are still commonly used even in patients without other indication for treatment such as asthma, chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA), despite their association with some worsened outcomes. Macrolides, on the other hand, have been shown to decrease frequency of exacerbation and improve quality of life. The dipeptidyl peptidase-1 inhibitor, brensocatib, inhibits activation of neutrophil serine proteases, including neutrophil elastase. In a phase 3 trial, brensocatib decreased the frequency of exacerbation, delayed time to first exacerbation, slowed the decline in lung function and improved quality of life. It recently became the first pharmacologic treatment approved by the U.S. Food and Drug Administration (FDA) for the treatment of bronchiectasis. Other treatment options are being investigated.

Summary:

Anti-inflammatory therapy is one of the integral components of treatment for people with bronchiectasis.

01 Mar 2026·Journal of Cystic Fibrosis

Cystic fibrosis year in review 2025

Review

Author: Lopes de Bragança, Raquel ; T Pallenberg, Sophia ; Párniczky, Andrea ; Zamarrón de Lucas, Ester

Cystic fibrosis (CF) is being reshaped by CFTR modulators (CFTRm), yet infection, inflammation, and multisystem comorbidities persist. This review of the 2025 CF literature summarizes how CF is evolving into a chronic, heterogeneous condition in the modulator era. First, we discuss the consolidation of elexacaftor/tezacaftor/ivacaftor (ETI) and next-generation modulators, highlighting durable gains in lung function and survival alongside persistent gaps in eligibility, access, and long-term safety, particularly for individuals with advanced structural lung damage or class I variants. Second, emerging mutation-agnostic therapy strategies are outlined, including ENaC blockade, neutrophil-directed anti-inflammatories like brensocatib, and gene and nucleic acid-based therapeutic approaches . Third, we examine airway infection and inflammation: while ETI reduces pathogen detection and systemic inflammatory markers, chronic Pseudomonas aeruginosa and heterogeneous neutrophilic endotypes frequently persist, and mucosal immune defects remain incompletely corrected. In this context, bacteriophage therapy has emerged as a candidate for multidrug-resistant infections, while microbiome-focused interventions show limited clinical impact despite clear shifts in microbial communities. Finally, as survival improves, pregnancy, age-related malignancy, and cardiovascular disease are becoming increasingly relevant, necessitating new models of multidisciplinary, lifespan care. Collectively, these developments mark a shift towards equitable, lifelong, system-level management of health in an aging and increasingly diverse CF population.

01 Mar 2026·Respiratory Investigation

Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial

Article

Author: Goto, Yuhei ; Teper, Ariel ; Chalmers, James D ; Zhang, Xiangmin ; De Soyza, Anthony ; Burgel, Pierre-Régis ; Li, Sherry ; Morimoto, Kozo ; Fernandez, Carlos ; Hasegawa, Naoki ; Daley, Charles L ; Metersky, Mark L ; Mauger, David

BACKGROUND:

In the ASPEN trial (NCT04594369), brensocatib 10 mg and 25 mg significantly reduced the burden of pulmonary exacerbations (annualized rate [primary endpoint], time to first, proportion exacerbation-free) over 52 weeks vs placebo in patients with bronchiectasis; brensocatib 25 mg significantly reduced lung function decline and nominally significantly improved patient-reported symptoms. Here we report efficacy and safety for Japanese patients.

METHODS:

Adults with bronchiectasis with ≥2 exacerbations in the 12 months before screening were randomized to once-daily brensocatib (10 mg or 25 mg) or placebo for 52 weeks. Endpoints included annualized exacerbation rate, time to first exacerbation, proportion remaining exacerbation-free, change from baseline in lung function, severe exacerbation rate, and change from baseline in patient-reported symptoms.

RESULTS:

Baseline characteristics of Japanese patients (n = 87) were generally consistent across groups. Brensocatib 10 mg and 25 mg reduced the annualized exacerbation rate vs placebo (rate ratio, 0.37 [95 % CI, 0.16-0.87]; 0.32 [0.14-0.75]), prolonged time to first exacerbation, and increased odds of remaining exacerbation-free. The annualized severe exacerbation rate was lower with brensocatib 10 mg and 25 mg vs placebo (rate ratio, 0.11 [0.01-1.04]; 0.30 [0.06-1.62]). Brensocatib, particularly at the 25 mg dose, also reduced lung function decline vs placebo (LS mean difference: forced expiratory volume in 1 s, 97 mL [95 % CI, 32-162]; forced vital capacity, 164 mL [84-244]) and improved patient-reported symptoms. Adverse events were similar across groups.

CONCLUSIONS:

Consistent with overall ASPEN results, brensocatib 10 mg and 25 mg reduced exacerbation frequency vs placebo in Japanese patients with bronchiectasis. Lung function, patient-reported symptoms, and safety data were consistent with overall ASPEN trial results.

CLINICAL TRIAL REGISTRATION:

NCT04594369.

109

News (Medical) associated with Brensocatib

10 Apr 2026

·endpoints.news

Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim

→ A decorated GLP-1 pioneer is retiring at Novo Nordisk . Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the building” after 36 years with Novo. Knudsen won the Breakthrough Prize last year with Jens Juul Holst of the Novo Nordisk Foundation Center for Basic Metabolic Research, along with three other scientists, for discovering the peptide that has rocked the industry. She created liraglutide , which is sold as Saxenda for weight loss and Victoza for type 2 diabetes. And while Eli Lilly means business as Novo’s fiercest competitor in the obesity space — adding another approval last week with its GLP-1 pill Foundayo — Ozempic and Wegovy have become household names as Knudsen’s long career draws to a close. “To have played such a pivotal role in advancing science that has meant so much to so many people —that is a privilege beyond measure,” Knudsen wrote. → As it readies itself to release crucial Phase 3 data on its weight loss candidate, Boehringer Ingelheim has lured an obesity specialist away from Novo Nordisk. According to a LinkedIn post , Sylvia Shubert has joined the German drugmaker as SVP of obesity and liver health. She will have much to do in her new role: The American Diabetes Association’s annual meeting in June will see the presentation of data from two late-stage trials of survodutide , the GLP-1 and glucagon agonist that grew out of a 2011 metabolic drug development collaboration between Boehringer and Zealand Pharma . If the data are positive, the company will want to gear up for the shot’s launch in the increasingly competitive obesity space. Before moving to Boehringer, Shubert spent nearly two years at Novo as VP and US therapeutic area head for obesity. She helped oversee the sale of Wegovy, including its launch in new uses — for reducing the risk of cardiovascular events and treating the fatty liver disease MASH. Her experience might come in handy at Boehringer, since survodutide is also in late-stage MASH trials. Earlier, Shubert spent three and a half years at J&J and nearly 14 years at Novartis . → Roche ’s radiotherapy partner Orano Med has tapped Frederic Desdouits as CEO. The Pierre Fabre alum was on the board of directors at TreeFrog Therapeutics before he became CEO of the French stem cell biotech in 2021. Mark Rothera , the former CEO of Orchard Therapeutics , Silence Therapeutics and Viracta Therapeutics , replaced Desdouits at TreeFrog in December. Orano Med also partnered with Sanofi for their radiopharmaceutical AlphaMedix in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Despite encouraging data , Sanofi disclosed in its Q4 update that it deprioritized the asset, opening the door for Perspective Therapeutics to potentially compete with Novartis’ Lutathera . → Dutch ADC developer Byondis has promoted Christoph Korpus to replace Jacques Lemmens as CEO. Lemmens will still chair the board of the company he founded. The new chief executive wrapped up an eight-year tenure with Merck KGaA in December 2024 and became CBO at Byondis in January 2025. Korpus was elevated to director, global business development and licensing oncology at Merck KGaA, a job title he kept for his last three years at the German pharma. → BioCryst has plucked Sandeep Menon from Alnylam and he will lead R&D at the Orladeyo maker, which snapped up another hereditary angioedema candidate when it bought Astria Therapeutics last fall. Menon was chief development officer, head of clinical development and safety for Alnylam, playing a pivotal role in the approval of its heart drug Amvuttra . He held multiple positions over a 13-year career with Pfizer , including CSO, BioMedicine AI and digital sciences. Jon Stonehouse retired from BioCryst on Dec. 31 and handed the reins to commercial chief Charlie Gayer . → Days after Endpoints News exclusively revealed Phase 1b data for Enveda ’s eczema candidate ENV-294 , CEO Viswa Colluru wrote on LinkedIn that Inhwan Kim has been promoted to chief strategy officer. Kim spent the last 18 months as SVP, portfolio strategy & operations. “Three years ago, I came across Enveda in a random late-night LinkedIn post and found its core thesis — to discover novel medicines from life’s chemistry, refined for biological relevance over billions of years of natural R&D — so compelling that I applied on the spot, hoping to be part of the story,” Kim wrote in a separate LinkedIn post . Three years later, Colluru said the new position “formalizes what’s already been true: Inhwan is one of the people who decides what Enveda becomes.” → Peter Anastasiou has been called up from the board of directors to take the COO job at Harmony Biosciences , while Rapport Therapeutics CFO Troy Ignelzi and ex- Sage chairman Geno Germano each nab a spot on the board. Anastasiou has been a board member at Harmony since 2023 and ran Capsida Biotherapeutics from 2022-25 following a 12-year run at Lundbeck . In September, Capsida said a patient died in a trial that was evaluating its gene therapy for a rare brain disorder, and Anastasiou’s LinkedIn page indicates that he left the company a month later. The biotech later revealed in an open letter that the patient died from cerebral edema. Former Acelyrin chief Mina Kim is still listed as interim CEO on Capsida’s website. Harmony also said that Valor Equity Partners ’ Antonio Gracias will step down from the board. → Overcoming a CRL to finally win the first-ever FDA approval for a Barth syndrome treatment, Stealth BioTherapeutics has promoted David Brown to CSO. Few people know the company as well as Brown, who advised Stealth for seven years before joining the team as senior director, scientific and technical innovation in 2019. He moves up to the CSO slot after two years as SVP of discovery. “I am energized by the work we do at Stealth every day to translate deep knowledge of mitochondrial bioenergetics into new medicines for people facing debilitating diseases,” Brown said in a press release . → Norwegian I/O player Lytix Biopharma has selected Novo Nordisk alum Renée Christine Amundsen as COO. Amundsen left Novo last year and was corporate VP for the diabetes commercial unit. Lytix is studying an oncolytic molecule called ruxotemitide as a monotherapy and in combination with Merck ’s Keytruda . → Tenpoint Therapeutics reached the regulatory checkered flag in January with an FDA approval for its presbyopia eye drop Yuvezzi . This week, Tenpoint has welcomed Stephen Lane as CMO. Lane held this position at eye care specialist Alcon , where he was also head of medical safety. When the approval came through, Tenpoint said it hauled in a combined $235 million from an $85 million Series B and a $150 million debt facility. → Joti Marango has landed at Gaithersburg, MD-based Remedy Plan Therapeutics as chief financial and business officer. The former Aptose exec had juggled the roles of COO and CFO at Ikena Oncology , which reverse merged with Inmagene and rebranded to ImageneBio under the ticker $IMA . “With our first oncology study now underway, our differentiated approach to NAMPT inhibition positions us well to tackle increasingly broader segments of the oncology market,” Marango said in a statement . → TuHURA Biosciences , which did a reverse merger of its own with Kintara , has brought in Amanda Garofalo as SVP of clinical operations. The EMD Serono vet also led clinical operations at Parabilis Medicines , a cancer biotech co-founded by Greg Verdine that was once known as FogPharma . After the Kintara agreement, TuHURA then merged with Kineta and picked up a VISTA-inhibiting monoclonal antibody that’s now codenamed TBS-2025 . → Palvella Therapeutics is back for the second time in the last three editions of Peer Review, hiring Kent Taylor as SVP of sales. Taylor had the same responsibilities at Arcutis Biotherapeutics and was VP of sales, dermatology for the inflammation & autoimmunity group at Incyte . We told you that Jennifer McDonough jumped to Palvella last month as SVP of market access and patient services. → Mineralys Therapeutics CEO Jon Congleton has punched his ticket to the board of directors at Avalyn Pharma , the pulmonary fibrosis specialist that filed its S-1 paperwork this week. It’s his second appointment in as many weeks after joining the board at Immunic . → Stoke Therapeutics has added Pfizer veteran Clare Kahn to its board of directors. Kahn has spent the last five years on the board at Solid Biosciences , where Stoke CEO Ian Smith is chairman. Stoke and Biogen are currently testing a Dravet syndrome drug called zorevunersen in a Phase 3 study. → The non-opioid pain experts at Latigo Biotherapeutics have elected Insmed CFO Sara Bonstein to the board of directors. Insmed had a rough go of it this week as the prospects of a label expansion for Brinsupri continue to dim . Meanwhile, Latigo is hoping its Nav1.8 inhibitor can set up a showdown with Vertex ’s Journavx . → Cleveland, OH-based cell and gene therapy maker Abeona Therapeutics has made room for Syndax Pharmaceuticals CFO Keith Goldan on the board of directors. Goldan held the CFO post at Optinose from 2017-22.

Executive ChangePhase 3Drug Approval

08 Apr 2026

·www.fiercepharma.com

Insmed terminates development of Brinsupri in another indication after midstage HS flop

With a second trial failure, the shine is coming off of Insmed's Brinsupri, which still is expected to become a blockbuster in its first full year on the market in 2026. It was approved in August as a treatment for the chronic lung condition bronchiectasis. For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand its use into a new indication. The New Jersey biotech revealed that a phase 2b study of Brinsupri in adults with moderate to severe hidradenitis suppurativa (HS) has failed to achieve its primary or secondary endpoints for either of its 10 mg or 40 mg once-daily treatment arms. With the result, the company will terminate the program. The flop comes after Insmed reported the misfire of another Brinsupri trial, testing the first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor in patients with chronic rhinosinusitis without nasal polyps (CRSsNP).That phase 2 study was similarly unsuccessful, as it failed to hit any of its primary or secondary endpoints with either the 10 mg or 40 mg dose. The result was conclusive enough that Insmed also discontinued Brinsupri’s development in that indication.In the HS study of 214 patients, Brinsupri failed to top placebo, with those in the 10 mg and 40 mg treatment arms experiencing reductions in their total abscess and inflammatory nodule (AN) counts of 46% and 40%, respectively, compared to 57% in the control group. HS is an inflammatory skin condition that causes painful lumps, abscesses and scarring in the sweat gland areas. Treatment-emergent adverse events (TEAEs) were more prevalent in the 10 mg arm, at 55%, than in the placebo (46%) or 40 mg (43%) groups, with three serious TEAEs among those in the 10 mg group compared to one each in the other treatment arms. A lack of established animal models in HS “makes clinical development particularly challenging” in the indication, Insmed’s chief medical officer, Martina Flammer, M.D., said in a release.“While we are disappointed in the results, we hope that insights gained from this study will contribute to the broader scientific understanding of HS,” Flammer added.The "silver lining" of the trial, according to analysts at Mizuho Securities, is that it confirmed Brinsupri's "excellent safety/tolerability profile." Insmed’s failure in the HS study “does not come as a surprise, given the challenges in HS clinical trials (particularly due to high placebo rates) and the lack of preclinical evidence to support DPP1 inhibition in the indication,” Matt Phipps, Ph.D., an analyst with William Blair, wrote in a note to clients. With expectations “very low” for the readout, there is no change to Insmed’s valuation, Phipps said, adding that he anticipates “minimal impact,” on the company’s shares.Insmed’s share price traded up nearly 1% before U.S. markets opened on Wednesday. By contrast, when Insmed revealed in December that it had flunked in CRSsNP—an indication that would have brought a large patient population—analysts from Mizuho sliced their peak annual sales projection for Brinsupri from $16 billion to $11 billion. Brinsupri was approved in August of last year as a treatment for a chronic lung condition, bronchiectasis. Despite being on the market for just four-plus months, Insmed reported Brinsupri’s sales at $173 million last year. Consensus estimates for first-quarter sales are at $198 million, according to Visible Alpha.

Drug ApprovalPhase 2Clinical ResultPhase 3

08 Apr 2026

·endpoints.news

Insmed shelves Brinsupri in skin disease after mid-stage flop

Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill in sinus inflammation at the end of last year. The study in HS, called CEDAR, was a comprehensive bust. Insmed revealed late on Tuesday that both doses of Brinsupri were outperformed by placebo on the primary endpoint. After four months’ treatment, patients with moderate-to-severe disease given 10 mg and 40 mg pills once daily had their total abscess and inflammatory nodule count reduced by 45.5% and 40.3%, respectively. The reduction in the placebo group was 57.1%. The DPP1 inhibitor failed on all the trial’s secondary efficacy endpoints, too. According to the study’s protocol on the federal clinical trials database, these included various measures of skin improvement, such as the proportion of subjects hitting a goal called HiSCR50, which represents a reduction of at least 50% in the number of abscesses and inflammatory nodules, with no increase in abscess or draining tunnel count. Insmed will end CEDAR without seeing through the year-long open-label part of its design. The company said the study reported no new safety signals, including in the 40 mg arm, which is the highest dose of Brinsupri it has yet tested. Serious treatment-emergent adverse events were seen in three patients given the 10 mg dose of Brinsupri and one patient each in the 40 mg and placebo arms. Insmed’s chief medical officer Martina Flammer said in a press release that as there are no established animal models in HS, clinical development is “particularly challenging.” This was similar to the defense she offered when Brinsupri failed in Phase 2 in chronic rhinosinusitis in December. In rhinosinusitis, the drug was also beaten by placebo, though not by as wide a margin as in the HS data. Insmed licensed the molecule from AstraZeneca a decade ago, paying $30 million upfront and promising a potential $120 million in biobucks. Brinsupri was approved last August for patients who have the lung disease bronchiectasis but don’t have cystic fibrosis. Analysts from Stifel wrote in a Tuesday note that HS was the final indication in which Insmed will test Brinsupri. Instead, the company plans to look at new, internally developed DPP1 inhibitors in new indications — ones for which animal models are available, hopefully increasing the chances of success in future proof-of-concept trials. In fairness to Insmed, HS is a difficult disease to treat. Incyte’s JAK1 inhibitor pill povorcitinib succeeded in two pivotal HS trials just over a year ago, but the data were regarded as disappointing compared with drugs that are already available for HS, like UCB’s Bimzelx. And last fall, MoonLake Immunotherapeutics’ IL-17A/F inhibitor sonelokimab hit in one of its pivotal HS trials but failed in the other, wiping vast amounts off the company’s market value. In defiance, the company has decided to press on with a BLA filing in September.

Clinical ResultDrug ApprovalPhase 3Phase 2

100 Deals associated with Brensocatib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15638

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-cystic fibrosis bronchiectasis	United States	Insmed, Inc.	12 Aug 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchiectasis	NDA/BLA	European Union	Insmed, Inc.	-
Bronchiectasis	NDA/BLA	United Kingdom	Insmed, Inc.	-
COVID-19	Phase 3	United Kingdom	Insmed, Inc.	05 Jun 2020
Hidradenitis Suppurativa	Phase 2	United States	Insmed, Inc.	16 Dec 2024
Hidradenitis Suppurativa	Phase 2	Australia	Insmed, Inc.	16 Dec 2024
Hidradenitis Suppurativa	Phase 2	Bulgaria	Insmed, Inc.	16 Dec 2024
Hidradenitis Suppurativa	Phase 2	Canada	Insmed, Inc.	16 Dec 2024
Hidradenitis Suppurativa	Phase 2	France	Insmed, Inc.	16 Dec 2024
Hidradenitis Suppurativa	Phase 2	Germany	Insmed, Inc.	16 Dec 2024
Hidradenitis Suppurativa	Phase 2	Greece	Insmed, Inc.	16 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05090904 (WILLOW-CF, CTgov)	Phase 2	Cystic Fibrosis	29	Brensocatib (Brensocatib 10 mg)	mrnukubesj(eceivdfvdt) = sseeokspno crmoffmqhh (hffrummbsu, 41.3) View more	-	12 Mar 2026
				Brensocatib (Brensocatib 25 mg)	mrnukubesj(eceivdfvdt) = lrvsnmxsqq crmoffmqhh (hffrummbsu, 25.9) View more
NCT06013241 (BiRCh, AAAAI2026)	Phase 2	Chronic rhinosinusitis without nasal polyps	288	Mometasone furoate nasal sprayBrensocatib 10mg film-coated tablets PO QD + Mometasone furoate nasal sprayBrensocatib 10mg film-coated tablets PO QD	pldivgvyvd(aszepkyhup) = gvsqneoyvh sixlabgqya (xpmkxdvnwo ) View more	Positive	27 Feb 2026
				Brensocatib 40mg film-coated tablets PO QDMometasone furoate nasal sprayablets PO QD + Brensocatib 40mg film-coated tablets PO QDMometasone furoate nasal spray	pldivgvyvd(aszepkyhup) = juwehaczhm sixlabgqya (xpmkxdvnwo ) View more
NCT04594369 (ASPEN, CTgov)	Phase 3	Non-cystic fibrosis bronchiectasis	1,767	Brensocatib 25 mg (Brensocatib 25 mg)	kpxbxfbabb = drsizinkqs hhonpgtcpg (clbjsvsnxt, szxteqjyae - uiuwiwizfa) View more	-	16 Dec 2025
				Placebo (Placebo)	kpxbxfbabb = awckofjsuc hhonpgtcpg (clbjsvsnxt, eblyuwursj - knbbpodovj) View more
NCT04594369 (ASPEN, FDA_CDER) Manual	Phase 3	Non-cystic fibrosis bronchiectasis	1,721	Placebo	gjuseyqgyt(odggvnklnx) = wwmxkncpxe sgflgcccyj (jtstgrqczt ) View more	Positive	12 Aug 2025
				BRINSUPRI 10 mg	gjuseyqgyt(odggvnklnx) = cdocnsdfng sgflgcccyj (jtstgrqczt ) View more
NCT03218917 (WILLOW, FDA_CDER) Manual	Phase 2	Non-cystic fibrosis bronchiectasis	256	BRINSUPRI 10 mg	-	Positive	12 Aug 2025
				BRINSUPRI 25 mg
NCT04594369 (ASPEN, ATS2025)	Phase 3	Non-cystic fibrosis bronchiectasis Neutrophil serine proteases (NSPs) \| neutrophil elastase	-	Brensocatib 10mg	wglpkyuhji(irevrfixxk) = ddisgfxxfk ctuwuiriot (lwdemlwahr ) View more	Positive	16 May 2025
				Brensocatib 25mg	wglpkyuhji(irevrfixxk) = fyvavberux ctuwuiriot (lwdemlwahr ) View more
NCT04594369 (ASPEN, Pubmed \| N Engl J Med)	Phase 3	Bronchiectasis neutrophilic inflammation	1,721	Brensocatib 10 mg	vuvlingqce(ceeilsrbxi) = higher incidence with brensocatib kjdwctdjpm (tvjhstolwf )	Positive	24 Apr 2025
				Brensocatib 25 mg
NCT04594369 (ASPEN, PRNewswire) Manual	Phase 3	Bronchiectasis	-	Brensocatib 10 mg	rtqhamumum(lxkwbjeczf) = ikdekzuewq bxzfflpkoi (caabctixtt ) View more	Positive	08 Oct 2024
				Brensocatib 25 mg	rtqhamumum(lxkwbjeczf) = vmiqcdppet bxzfflpkoi (caabctixtt ) View more
NCT04594369 (ASPEN, Company_Website) Manual	Phase 3	Bronchiectasis	1,721	BrensocatibBrensocatib 10 mg	xrsmsatrkk(ldnkmgnqwn) = gsbysujkdz kadsxrnyuz (whciphczik ) View more	Positive	28 May 2024
				Brensocatib 25 mgBrensocatib 25 mg	xrsmsatrkk(ldnkmgnqwn) = lvvufahxgv kadsxrnyuz (whciphczik ) View more
NCT05673603 (ATS2024) Manual	Phase 1	Non-cystic fibrosis bronchiectasis	28	Brensocatib (Subjects with mild renal impairment)	pkrhoyobne(vhekccsflg) = There were no treatment-emergent AEs, serious AEs, or death during this study. crmvuhzpcz (mwneojlcud )	Positive	22 May 2024
				Brensocatib (Subjects with moderate renal impairment)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis